

**OPTN Ad Hoc Disease Transmission Committee  
COVID-19 Summary of Evidence Workgroup  
Meeting Summary  
April 14, 2022  
Conference Call**

**Ricardo La Hoz, MD, FACP, FAST, FIDSA, Chair  
Lara Danziger-Isakov, MD, MPH, Vice Chair**

## **Introduction**

The OPTN Ad Hoc Disease Transmission Committee (the Committee) met via Microsoft Teams teleconference on 04/14/2022 to discuss the following agenda items:

1. Review of proposed changes to April 2022 SARS-CoV-2 Summary of Evidence

The following is a summary of the (Sub)Committee's discussions.

### **1. Review of proposed changes to April 2022 SARS-CoV-2 Summary of Evidence**

The committee reviewed suggested changes and edits to the April 2022 SARS-CoV-2 Summary of Evidence.

#### Summary of discussion:

Committee members agreed on changes made to reflect the prevalence of BA.2 and its sublineages. This was done in order to highlight the possibility of more transmissible infection. A committee member also pointed out that this variant still does not evade molecular testing.

The Chair emphasized that some of the verbiage regarding positive lower respiratory testing (LRT) results could imply that transmission from donor to recipient can be stopped.

One member of the workgroup pointed out that the document should recognize that non-airway transmission of SARS-CoV-2 is possible. The Chair was hesitant to add these changes because of the possibility of transmission from other routes. Committee members suggested stating that non-airway transmission is a possibility, and the member explained that this should be posed as a potential consequence of transplantation. The committee members decided on language that conveys the only confirmed donor derived infection is through lung transplantation, but there is a risk of non-airway transmission that is not yet confirmed.

One member of the workgroup and the Chair discussed possible complications for recipients due to SARS-CoV-2 transmission. The member highlighted the risk of liver thrombosis, while the Chair called attention to the risk of bias in that claim. The committee eventually agreed to acknowledge this risk in the Summary of Evidence by including thrombotic events as an unknown long-term effect.

#### Next Steps:

The committee will send the April 2022 SARS-CoV-2 Summary of Evidence to the Executive Committee for Review and will revisit making changes in three months.

**Upcoming Meetings**

- April 25, 2022, 12 pm ET (teleconference) – Pediatric Public Comment Review

## Attendance

- **Workgroup Members**
  - Ann Woolley
  - Charles Marboe
  - Dong Lee
  - Emily Blumberg
  - Gary Marklin
  - Helen Te
  - Jason Goldman
  - Lara Danziger-Isakov
  - Ricardo La Hoz
  - Sam Ho
  - Stephanie Pouch
  - Timothy Pruett
  - Kelly Dunn
  - Marian Michaels
  
- **HRSA Representatives**
  - Jim Bowman
  - Marilyn Levi
  
- **CDC Staff**
  - Ian Kracalik
  - Pallavi Annambhotla
  - Rebecca Free
  - Sridhar Basavaraju
  
- **FDA Staff**
  - Scott Brubaker
  
- **UNOS Staff**
  - Susie Sprinson
  - Cole Fox
  - Courtney Jett
  - Sandy Bartal
  - Susan Tlusty